Deadline: March 1, 2013 (Letters of Intent)

The Leukemia & Lymphoma Society has issued new Requests for Proposals through its Translational Research Program to support researchers in six critical areas of unmet medical need. The RFPs mark LLS’s aggressive and proactive approach to addressing the challenge of improving outcomes for cancer patients with particularly urgent needs.

The LLS Translational Research Program is designed to help accelerate the movement of promising discoveries from lab to clinic. The goal of translational research is to reduce the time between laboratory findings and actual treatment.

The society aims to stimulate more academic research in the following areas: new immunotherapeutics for patients with acute myelogenous leukemia; novel therapeutics for patients with non-cutaneous T-cell malignancies; introduction of novel agents in the treatment of patients with diffuse large B-cell lymphoma and mantle cell lymphoma; therapies for patients with myelodysplastic syndromes who have failed hypomethylating agents; therapies for new targets such as bromodomains, methylation, and other epigenetic approaches for patients with high-risk myeloma; and research that addresses long-term and late effects of blood cancer therapies.

Applicants (principal investigators) must hold an M.D., Ph.D., or equivalent degree, and work in a nonprofit organization (domestic or foreign), university, college, hospital, or lab. Applications may involve multiple institutions and the applicant should have an independent research or academic position. Applicants need not be United States citizens. Each grant provide up to $600,000 over three years.

Visit the LLS Web site for complete program guidelines and application procedures.

Contact:
Link to Complete RFP

Deadline: February 15, 2013 (Letters of Intent)

As part of its mission to find a cure for ulcerative colitis and Crohn’s disease, the Kenneth Rainin Foundation is inviting Letters of Intent for its 2013 Innovator Awards Program for Inflammatory Bowel Disease.

The program supports innovative “out-of-the-box” research projects that are potentially transformative to the foundation’s efforts to diagnose, treat, and/or cure IBD. The program’s key criteria for funding consideration include innovation, strong collaboration, scientific merit, and a high potential for success, as well as projects that, due to their innovative nature, may not be eligible for funding from the National Institutes of Health or other more traditional sources.

The program is open to tenure-track professors (or the equivalent) at all levels from any scientific discipline and from any nonprofit research institution worldwide. Interdisciplinary collaboration is strongly encouraged.

The Innovator Awards provide $100,000 for one year for proof of principle research. Innovator Award recipients who have demonstrated significant research progress are eligible for longer-term support through the KRF Breakthrough Awards Program. Innovator Awardees are evaluated for potential Breakthrough Awards at the end of their initial year of funding. One-page Letters of Intent, which must include the basic idea and the central experiment, will be accepted online at the KRF Web site from January 15 to February 15, 2013. Invited full applications will be due by May 1, 2013.

For complete program information and application instructions, visit the KRF Web site.

Contact:
Link to Complete RFP

Deadline: January 3, 2013

The Leukemia & Lymphoma Society has released a Request for Applications for the New Idea Award, a new grant program designed to support the development of safer and more effective treatment paradigms for patients with hematological malignancies. Specifically, the program represents a concept grant to support academic researchers with innovative therapy ideas that are substantially different from current standard treatments and may advance to clinical testing in the short term. It is anticipated that each project funded through the program will be unique and represent a high-risk, potentially high-reward opportunity.

The goal of this RFA is to evaluate novel concepts that could lead to significant improvements in the clinical outcomes, including quality of life, of patients with hematological malignancies. Grants will support initial exploration of untested but potentially transformative research ideas and treatment approaches. Applicants must succinctly describe the innovative idea/approach and a method for testing it within one year. Upon completion of the one-year grant period, applicants will be evaluated on the extent to which their concept has been substantiated by initial testing, and promising projects may be selected for extended funding.

Up to eight grants of up to $100,000 will be awarded.

Investigators in academic laboratories are eligible to apply. Investigators must demonstrate that their research environment is equipped and suitable for the proposed study. Applicants need not be United States citizens or be associated with a U.S.-based institution. Applicants should hold a Ph.D., M.D., D.V.M., or equivalent degree.

Visit the Leukemia & Lymphoma Society Web site for complete program guidelines and application procedures.

Contact:
Link to Complete RFP